Epidemiology and Management of Kawasaki Disease

被引：47

作者：

Luca, Nadia J. C. ^{[1
,2
]}

Yeung, Rae S. M. ^{[2
,3
,4
]}

机构：

[1] Hosp Sick Children, Div Rheumatol, Toronto, ON M5G 1X8, Canada

[2] Univ Toronto, Dept Pediat, Toronto, ON, Canada

[3] Univ Toronto, Dept Immunol, Toronto, ON, Canada

[4] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada

来源：

DRUGS | 2012年 / 72卷 / 08期

关键词：

INTRAVENOUS GAMMA-GLOBULIN; STEROID PULSE THERAPY; MACROPHAGE ACTIVATION SYNDROME; CORONARY-ARTERY INVOLVEMENT; ADDITIONAL IMMUNE GLOBULIN; AMERICAN-HEART-ASSOCIATION; LONG-TERM MANAGEMENT; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; NATIONWIDE SURVEY; DIFFERENTIAL-DIAGNOSIS;

D O I：

10.2165/11631440-000000000-00000

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Kawasaki disease (KD) is an acute systemic vasculitis affecting young children and is rising in incidence worldwide. It is most common in children <5 years of age, males and those of Asian ethnicity. It is an important cause of acquired heart disease in children. Standard treatment with high-dose aspirin (acetylsalicylic acid; ASA) and intravenous immune globulin (IVIG) has been shown to decrease the rate of coronary artery aneurysm development. Anticoagulation has an important place in the management of KD, although guidance based on evidence is lacking. Treatment of refractory KD is an area under intense study and may include IVIG, corticosteroids and/or tumour necrosis factor (TNF)-alpha inhibitors among immunosuppressive agents. Acute complications of KD include myocarditis/KD shock syndrome and macrophage activation syndrome, which necessitate appropriate awareness in order to initiate proper management.

引用

页码：1029 / 1038

页数：10

共 56 条

[51] Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin [J].

Suzuki, Hiroyuki ;

Terai, Masaru ;

Hamada, Hiromichi ;

Honda, Takafumi ;

Suenaga, Tomohiro ;

Takeuchi, Takashi ;

Yoshikawa, Norishige ;

Shibuta, Shoichi ;

Miyawaki, Masakazu ;

Oishi, Ko ;

Yamaga, Hironobu ;

Aoyagi, Noriyuki ;

Iwahashi, Seiji ;

Miyashita, Ritsuko ;

Onouchi, Yoshihiro ;

Sasago, Kumiko ;

Suzuki, Yoichi ;

Hata, Akira .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (10) :871-876

[52] Hemophagocytic Lymphohistiocytosis and Kawasaki Disease: Combined Manifestation and Differential Diagnosis [J].

Titze, Ulf ;

Janka, Gritta ;

Schneider, E. Marion ;

Prall, Friedrich ;

Haffner, Dieter ;

Classen, Carl Friedrich .

PEDIATRIC BLOOD & CANCER, 2009, 53 (03) :493-495

[53] Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: Analysis from the 17th nationwide survey [J].

Uehara, Ritei ;

Yashiro, Mayumi ;

Oki, Izumi ;

Nakamura, Yosikazu ;

Yanagawa, Hiroshi .

PEDIATRICS INTERNATIONAL, 2007, 49 (04) :427-430

[54] Initial intravenous gammaglobulin treatment failure in Kawasaki disease [J].

Wallace, CA ;

French, JW ;

Kahn, SJ ;

Sherry, DD .

PEDIATRICS, 2000, 105 (06) :art. no.-e78

[55] Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? [J].

Williams, RV ;

Wilke, VM ;

Tani, LY ;

Minich, LL .

PEDIATRICS, 2002, 109 (01) :E4

[56] The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β [J].

Yin, MJ ;

Yamamoto, Y ;

Gaynor, RB .

NATURE, 1998, 396 (6706) :77-80

← 1 2 3 4 5 6 →